Over time, we have learned that patients with EGFR-mutated advanced NSCLC derive the greatest benefit from EGFR TKI therapy, which is superior to chemotherapy in terms of response rate, quality of life, and progression-free survival, although not in overall survival due to crossover in clinical trials, with a recent exception (35). This evidence concerns the gene EGFR and non-small cell lung carcinoma.